Category survey

Competence Network Dementia – Epidemiology Investments > €500k Germany Alzheimer’s disease & other dementias 2016    

Competence Network Dementia – FTLD Investments > €500k Germany Alzheimer’s disease & other dementias 2016    

Therapy and biomarker development for patients with amyotrophic lateral sclerosis Investments > €500k Germany Motor neurone diseases 2016    

Randomized, controlled study on the use of simvastatin in mild cognitive disorders Investments > €500k Germany Alzheimer’s disease & other dementias 2016    

Mitochondrial endophanotypes of Parkinson ‘s disease Investments > €500k Germany Parkinson’s disease & PD-related disorders 2016    

Competence Network – Parkinson disease Investments > €500k Germany Parkinson’s disease & PD-related disorders 2016    

Induced pluripotent stem cells as a model system for motoneuron diseases Investments > €500k Germany Motor neurone diseases 2016    

A new Generation of Drugs for ALzheimer’s disease based on in vitro and in silico experiments of beta-amyloid oligomers and in vivo tests Investments > €500k France Alzheimer’s disease & other dementias 2016    

PKR and danger molecules in Alzheimer’s disease Investments > €500k France Alzheimer’s disease & other dementias 2016    

Role of the purinergic receptor P2X7 in Alzheimer’s disease Investments > €500k France Alzheimer’s disease & other dementias 2016    

Innovating technology to characterize balance loss in Ecological setting of daily life: application to Parkinson’s disease Investments > €500k France Parkinson’s disease & PD-related disorders 2016    

Technology for the Search of Common Objects in the House Investments > €500k France Alzheimer’s disease & other dementias 2016    

Alzheimer’s desease and implicit motor learning Investments > €500k France Alzheimer’s disease & other dementias 2016    

Dopamine Gene therapy for the treatment of Motor and Non-motor symptoms of Parkinson disease. A translational program from Non-Human primate models to patients Investments > €500k France Parkinson’s disease & PD-related disorders 2016    

Safe & Easy Environment for Alzheimer’s disease and related disorders Investments > €500k France Alzheimer’s disease & other dementias 2016    

Microrobotic nasal endoscopy by OCT: impact of smell deficiency on neurodegenerative diseases Investments > €500k France Neurodegenerative disease in general 2016    

Spreading of Tau assemblies Investments > €500k France Alzheimer’s disease & other dementias|Neurodegenerative disease in general 2016    

Interaction of BIN1 and Tau: physiological functions and pathological consequences in Alzheimer’s disease. Investments > €500k France Alzheimer’s disease & other dementias 2016    

Neuronal allocation mechanisms of recent and remote memories in the normal and pathological brain Investments > €500k France Alzheimer’s disease & other dementias 2016    

Neuronal diversity in globus pallidus: from molecular profiling to function in voluntary movement Investments > €500k France Parkinson’s disease & PD-related disorders 2016    

VCP Interacting Drugs as a novel strategy for the treatment of Alzheimer’s disease Investments > €500k France Alzheimer’s disease & other dementias 2016    

The tVTA: a new member of basal ganglia with therapeutic potential Investments > €500k France Parkinson’s disease & PD-related disorders 2016    

Marqueurs précoces de la maladie de Parkinson liés aux dérèglements des voies de la survie cellulaire. Early markers of Parkinson’s disease related to disorders of cell survival pathways Investments > €500k France Parkinson’s disease & PD-related disorders 2016    

Utilisation de la protéomique quantitative ciblée et du marquage aux isotopes stables pour le diagnostic et l’étude des affections neurologiques et en particulier de la maladie d’Alzheimer. Use of targeted quantitative proteomics and stable isotope labeling for the diagnosis and…

Etude longitudinale en imagerie multimodale de la maladie d’Alzheimer à un stade précoce : biomarqueurs de détection et de progression et mécanismes physiopathologiques. Longitudinal study in multimodal imaging of Alzheimer’s disease at an early stage: biomarkers of detection and progression…

Impact d’un traitement précoce par amantadine sur les complications motrices induites par la L-DOPA dans la maladie de Parkinson : étude comparative randomisée versus placebo. Impact of early amantadine treatment on motor complications induced by L-DOPA in Parkinson’s disease: a randomized,…

Etude de la composante vasculaire dans la survenue de la maladie d’Alzheimer et des maladies apparentées. Study of the vascular component in the onset of Alzheimer’s disease and related diseases Investments > €500k France Alzheimer’s disease & other dementias 2016…

Relationship between serotonergic innervation, dopaminergic deficit and levodopa induced dopamine release patterns in PD treatment-related complications: a longitudinal imaging study Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Mobilizing the healthcare community towards an integrated approach to improving outcomes of patients with sleep disorders – Canadian Sleep and Circadian Network (CSCN) Investments > €500k Canada Neurodegenerative disease in general 2016    

The Neighbourhood Team Development Program: Promoting Resident Centeredness in Long-Term Care Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Dementia in the population: Trajectories of disease, health care use, and places of care Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Project of excellence in the field of neuroscience Investments > €500k Czech Republic Alzheimer’s disease & other dementias 2016    

In vivo assessment of brain neurotransmitter dysfunction and microglial activation in patients with REM sleep behavior disorder as early markers of parkinsonian disorders Investments > €500k Denmark Parkinson’s disease & PD-related disorders 2016    

Role of the synaptic proteins neuroligin-1 and neurexin-1 in Alzheimer’s disease Investments > €500k Denmark Alzheimer’s disease & other dementias 2016    

Establishment of demented dogs as a superior model for Alzheimer’s disease Investments > €500k Denmark Alzheimer’s disease & other dementias 2016    

Serotonergic modulation of Alzheimer-like disease in mice Investments > €500k Denmark Alzheimer’s disease & other dementias 2016    

Signal Processing for Diagnosis of Parkinson’s Disease from Noisy Speech Investments > €500k Denmark Parkinson’s disease & PD-related disorders 2016    

BIOPHYSICALLY ADJUSTED STATE-INFORMED CORTEX STIMULATION (BaSiCs): SHAPING THE FUNCTIONAL ARCHITECTURE OF NEURAL NETWORKS TO IMPROVE HUMAN BRAIN FUNCTION Investments > €500k Denmark Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

Aarhus Reseach Centre for Brain Aging and Dementia – ARCADIA Investments > €500k Denmark Alzheimer’s disease & other dementias 2016    

MOLECULAR LINKS BETWEEN DIABETES AND NEURODEGENERATIVE DISORDERS Investments > €500k Spain Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

EPIGENETIC AND ENVIRONMENTAL FACTORS BRACING COGNITIVE IMPAIRMENT AND LATE-ONSET DEPRESSION IN ELDERLY AND EARLY STAGES OF ALZHEIMER DISEASE Investments > €500k Spain Alzheimer’s disease & other dementias 2016    

THERAPEUTIC USE OF EPIGENETIC MODULATORS IN ONCOLOGICAL AND NEURODEGENERATIVE DISEASE Investments > €500k Spain Alzheimer’s disease & other dementias 2016    

Centre of Excellence in Research on Mitochondria, Metabolism and Disease (FinMIT) Investments > €500k Finland Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

Coupling factor 6, a circulating vasoactive peptide, in Alzheimer’s disease Investments > €500k Finland Alzheimer’s disease & other dementias|Neurodegenerative disease in general 2016    

Nanoparticle Assisted Brain in vivo Imaging Investments > €500k Finland Alzheimer’s disease & other dementias|Neurodegenerative disease in general 2016    

Validation and Clinical Implementation of Parkinson’s Disease and Breast Cancer Biomarkers for Diagnosis and Treatment Response Monitoring Investments > €500k Finland Parkinson’s disease & PD-related disorders 2016    

Modelling multi-factorial neurodegeneration in Parkinson’s disease: removing roadblocks towards the clinic Investments > €500k France Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

Pathophysiology of Parkinson’s disease Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Mechanisms of DJ-1 in an aging model of PD Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

The TAR DNA-Binding Protein (TDP-43) and Amyotrophic Lateral Sclerosis Investments > €500k Canada Motor neurone diseases 2016